335 related articles for article (PubMed ID: 38035056)
1. Current insights into the interplay between gut microbiota-derived metabolites and metabolic-associated fatty liver disease.
Dongoran RA; Tu FC; Liu CH
Tzu Chi Med J; 2023; 35(4):290-299. PubMed ID: 38035056
[TBL] [Abstract][Full Text] [Related]
2. Polysaccharides: The Potential Prebiotics for Metabolic Associated Fatty Liver Disease (MAFLD).
Guo Q; Li Y; Dai X; Wang B; Zhang J; Cao H
Nutrients; 2023 Aug; 15(17):. PubMed ID: 37686754
[TBL] [Abstract][Full Text] [Related]
3. New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.
Yang K; Song M
Nutrients; 2023 Sep; 15(18):. PubMed ID: 37764755
[TBL] [Abstract][Full Text] [Related]
4. Mining Gut Microbiota From Bariatric Surgery for MAFLD.
Wu WK; Chen YH; Lee PC; Yang PJ; Chang CC; Liu KL; Hsu CC; Huang CC; Chuang HL; Sheen LY; Liu CJ; Wu MS
Front Endocrinol (Lausanne); 2021; 12():612946. PubMed ID: 33897617
[TBL] [Abstract][Full Text] [Related]
5. Gut-liver axis in the progression of nonalcoholic fatty liver disease: From the microbial derivatives-centered perspective.
Luo L; Chang Y; Sheng L
Life Sci; 2023 May; 321():121614. PubMed ID: 36965522
[TBL] [Abstract][Full Text] [Related]
6. Hepatic Mitochondria-Gut Microbiota Interactions in Metabolism-Associated Fatty Liver Disease.
Bellanti F; Lo Buglio A; Vendemiale G
Metabolites; 2023 Feb; 13(3):. PubMed ID: 36984762
[TBL] [Abstract][Full Text] [Related]
7. Influence of Gut Microbiota and its Metabolites on Progression of Metabolic Associated Fatty Liver Disease.
Wang YY; Lin HL; Wang KL; Que GX; Cao T; Zhu LM; Yang X; Yang XF
Chin Med Sci J; 2023 Dec; 38(4):286-296. PubMed ID: 38097345
[TBL] [Abstract][Full Text] [Related]
8. The gut-liver axis: emerging mechanisms and therapeutic approaches for nonalcoholic fatty liver disease and type 2 diabetes mellitus.
Bhardwaj M; Mazumder PM
Naunyn Schmiedebergs Arch Pharmacol; 2024 Jun; ():. PubMed ID: 38861011
[TBL] [Abstract][Full Text] [Related]
9. Metabolic-Associated Fatty Liver Disease and Insulin Resistance: A Review of Complex Interlinks.
Barber TM; Kabisch S; Pfeiffer AFH; Weickert MO
Metabolites; 2023 Jun; 13(6):. PubMed ID: 37367914
[TBL] [Abstract][Full Text] [Related]
10. Gut microbiome and metabolic-associated fatty liver disease: Current status and potential applications.
Guo GJ; Yao F; Lu WP; Xu HM
World J Hepatol; 2023 Jul; 15(7):867-882. PubMed ID: 37547030
[TBL] [Abstract][Full Text] [Related]
11. Roles of gut microbes in metabolic-associated fatty liver disease.
Chen CY; Ho HC
Tzu Chi Med J; 2023; 35(4):279-289. PubMed ID: 38035063
[TBL] [Abstract][Full Text] [Related]
12. Effects of plant natural products on metabolic-associated fatty liver disease and the underlying mechanisms: a narrative review with a focus on the modulation of the gut microbiota.
Cai T; Song X; Xu X; Dong L; Liang S; Xin M; Huang Y; Zhu L; Li T; Wang X; Fang Y; Xu Z; Wang C; Wang M; Li J; Zheng Y; Sun W; Li L
Front Cell Infect Microbiol; 2024; 14():1323261. PubMed ID: 38444539
[TBL] [Abstract][Full Text] [Related]
13. Non-alcoholic fatty liver disease in patients with morbid obesity: the gut microbiota axis as a potential pathophysiology mechanism.
Cornejo-Pareja I; Amiar MR; Ocaña-Wilhelmi L; Soler-Humanes R; Arranz-Salas I; Garrido-Sánchez L; Gutiérrez-Repiso C; Tinahones FJ
J Gastroenterol; 2024 Apr; 59(4):329-341. PubMed ID: 38265508
[TBL] [Abstract][Full Text] [Related]
14. Vitamin C and vitamin D
Chen Q; Zhao L; Mei L; Zhao X; Han P; Liu J; Meng C; Li R; Zhong R; Wang K; Li J
Front Pharmacol; 2023; 14():1163694. PubMed ID: 37089915
[No Abstract] [Full Text] [Related]
15. Effects of Dietary Nutrients on Fatty Liver Disease Associated With Metabolic Dysfunction (MAFLD): Based on the Intestinal-Hepatic Axis.
Yao N; Yang Y; Li X; Wang Y; Guo R; Wang X; Li J; Xie Z; Li B; Cui W
Front Nutr; 2022; 9():906511. PubMed ID: 35782947
[TBL] [Abstract][Full Text] [Related]
16. Mapping the human oral and gut fungal microbiota in patients with metabolic dysfunction-associated fatty liver disease.
Niu C; Tu Y; Jin Q; Chen Z; Yuan K; Wang M; Zhang P; Luo J; Li H; Yang Y; Liu X; Mao M; Dong T; Tan W; Hu X; Pan Y; Hou L; Ma R; Huang Z
Front Cell Infect Microbiol; 2023; 13():1157368. PubMed ID: 37180439
[TBL] [Abstract][Full Text] [Related]
17. Targeting the Gut Microbiome to Treat Metabolic Dysfunction-Associated Fatty Liver Disease: Ready for Prime Time?
Lanthier N; Delzenne N
Cells; 2022 Aug; 11(17):. PubMed ID: 36078124
[TBL] [Abstract][Full Text] [Related]
18. Gut microbiota in MAFLD: therapeutic and diagnostic implications.
Alghamdi W; Mosli M; Alqahtani SA
Ther Adv Endocrinol Metab; 2024; 15():20420188241242937. PubMed ID: 38628492
[TBL] [Abstract][Full Text] [Related]
19. Metabolic-Associated Fatty Liver Disease and the Gut Microbiota.
Barber TM; Hanson P; Weickert MO
Endocrinol Metab Clin North Am; 2023 Sep; 52(3):485-496. PubMed ID: 37495339
[TBL] [Abstract][Full Text] [Related]
20. Microbial Dysbiosis Linked to Metabolic Dysfunction-Associated Fatty Liver Disease in Asians:
Yuan H; Wu X; Wang X; Zhou JY; Park S
Int J Mol Sci; 2024 Feb; 25(4):. PubMed ID: 38396863
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
